Abstract

Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease

Aging Clin Exp Res. 2021 Aug;33(8):2355-2359. doi: 10.1007/s40520-021-01917-9.Epub 2021 Jun 23.

Margalida Calafat 1 2, Carlos González-Muñoza 3, Marta Fortuny 1, Cristina Roig 3, Anna Calm 1, Antonio Mombiela 3, Fiorella Cañete 1 2, Federico Bertoletti 3, Laura González-González 1, Marta Teller-Martín 3, Jordi Gordillo 3, Míriam Mañosa 1 2, Esther Garcia-Planella 3, Eugeni Domènech 4 5 6

 
     

Author information

  • 1Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain.
  • 2Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
  • 3Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • 4Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain. eugenidomenech@gmail.com.
  • 5Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. eugenidomenech@gmail.com.
  • 6Gastroenterology and Hepatology Department, Hospital Universitari Germans Trias I Pujol, Carretera del Canyet s/n, 08916, Badalona, Catalonia, Spain. eugenidomenech@gmail.com.

Abstract

Background: Older age has been reported as a risk factor for severe SARS-CoV-2 disease (COVID-19). The impact of immunosuppressants (IMS) on COVID-19 is still under debate.

Aim: To describe the incidence and severity of COVID-19 in elderly patients with inflammatory bowel disease (IBD) in relation to the use of IMS.

Methods: IBD patients over 65 years of age were selected and grouped in terms of IMS use. Confirmed COVID-19, adherence to IST, comorbidities and concomitant non-IBD-related treatments between 1st of March 2020 to 1st of March 2021 were recorded.

Results: Out of 418 patients included, 89 (21.3%) were on IMS. Thirty-two patients (7.7%) had COVID-19, 7 of whom were on IMS (7.6% not on IMS vs. 7.9% on IMS; P = 0.933) and 7 (22%) patients died.

Conclusions: Incidence of COVID-19 among elderly IBD patients was similar to that reported in the background population, regardless of the use of IMS.

 

 

© Copyright 2013-2022 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.